ストックスクリーナーアプリを入手
0.326
0.31%
0.001
アフターアワーズ：
.32
-0.006
-1.84%
前日終値:
$0.325
開ける：
$0.325
24時間の取引高:
851.99K
Relative Volume:
0.31
時価総額：
$29.19M
収益：
-
当期純損益:
$-166.14M
株価収益率:
-0.1698
EPS:
-1.92
ネットキャッシュフロー:
$-139.92M
1週間 パフォーマンス:
+0.93%
1か月 パフォーマンス:
+30.50%
6か月 パフォーマンス:
-75.67%
1年 パフォーマンス:
-69.25%
1日の値動き範囲:
$0.325
$0.328
1週間の範囲:
$0.3205
$0.3288
52週間の値動き範囲:
$0.2157
$1.555
Allakos Inc Stock (ALLK) Company Profile
ALLK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.326 | 29.19M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-17 | ダウングレード | Jefferies | Buy → Hold |
| 2024-01-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | 再開されました | Jefferies | Buy |
| 2023-09-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-05-12 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-07 | 開始されました | Piper Sandler | Overweight |
| 2022-09-12 | ダウングレード | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-22 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-22 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-07-15 | 開始されました | Cowen | Outperform |
| 2021-05-18 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-15 | 開始されました | BofA Securities | Buy |
| 2020-12-21 | 開始されました | SVB Leerink | Outperform |
| 2020-02-27 | 開始されました | Barclays | Underweight |
| 2020-02-04 | 再開されました | Goldman | Neutral |
| 2018-08-13 | 開始されました | Goldman | Neutral |
| 2018-08-13 | 開始されました | Jefferies | Buy |
| 2018-08-13 | 開始されました | William Blair | Outperform |
すべてを表示
Allakos Inc (ALLK) 最新ニュース
Checking in on Allakos Inc (ALLK) after recent insiders movement - knoxdaily.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders - PR Newswire
Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million. - marketscreener.com
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share - MarketScreener
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos surges on reverse merger deal with Concentra Biosciences - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
Allakos agrees to Concentra Biosciences acquisition By Investing.com - Investing.com India
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com India
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com
Allakos Inc. (ALLK) reports earnings - Quartz
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - The Manila Times
Allakos Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Allakos Swings to Surprise Q4 Profit as Major Restructuring Takes Shape - StockTitan
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday - Defense World
The Curious Case of Allakos - substack.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 3 DAY APPLICATION DEADLINE ALERT - ACCESS Newswire
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
Allakos Inc (ALLK) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):